Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Kedudukan dalam Saham #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Harga Saham
$0.1559364
Disegerakkan terakhir: 2026-09-18
Modal Pasaran
$195.17K
Perubahan (1 hari)
6.60%
Perubahan (1 tahun)
-30.91%
Negara
GB
Perdagangan Fusion Antibodies plc (FAB)

Kategori

Healthcare
Pendapatan untuk Fusion Antibodies plc (FAB)
Pendapatan pada Sep 2025 TTM: $-2.06M
Menurut laporan kewangan terkini Fusion Antibodies plc, pendapatan semasa syarikat ialah $-2.06M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $-2.89M, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $-3.53M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Fusion Antibodies plc dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -256,061.35%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -94,754.12%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 149,694.82%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 194,783.51%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH